Post by Teva Pharmaceuticals

We’re proud to bring a new biosimilar treatment option to patients living with serious, vision-threatening retinal conditions across Europe – because when sight is at stake, access to high-quality care should not be a barrier. This launch is in line with our Pivot to Growth strategy, as we build a leading biosimilars business in areas of significant patient need – broadening access to biologic medicines through strong partnerships, broad commercial capabilities, and reliable supply. #Biosimilars #PatientAccess #PivotToGrowth